Skip to main content

Table 2 Factors related to the uptake of stomach cancer screeninga for lung cancer survivors

From: Factors related with colorectal and stomach cancer screening practice among disease-free lung cancer survivors in Korea

Variables All patients (N = 829) Male patients (N = 641) Female patients (N = 188)
% Age-adjusted OR (95% CI) Multivariate ORb (95% CI) % Age-adjusted OR (95% CI) Multivariate ORb (95% CI) % Age-adjusted OR (95% CI) Multivariate ORb (95% CI)
Receiving physician advice to screen for SPC
 No 19.8 1.0 1.0 19.5 1.0 1.0 20.8 1.0 1.0
 Yes 26.7 1.52 (1.09–2.11) 1.61 (1.14–2.26) 27.4 1.59 (1.09–2.32) 1.73 (1.17–2.56) 24.7 1.32 (0.66–2.63) 1.30 (0.61–2.80)
Perceived risk of SPC in lung cancer survivors
 Lower than general population (GP) 20.8 1.0 1.0 22.9 1.0 1.0 12.5 1.0 1.0
 Same or higher than GP 22.6 1.07 (0.60–1.91) 1.16 (0.63–2.13) 22.4 0.95 (0.51–1.79) 0.97 (0.50–1.88) 23.0 1.89 (0.40–8.92) 2.34 (0.44–12.43)
Monthly household income, ($US)
  < 1000 19.6 1.0 1.0 18.9 1.0 1.0 22.0 1.0 1.0
 1000–2999 21.8 1.11 (0.73–1.67) 1.03 (0.66–1.59) 22.5 1.20 (0.75–1.92) 1.06 (0.64–1.73) 19.5 0.79 (0.31–1.97) 1.10 (0.33–3.05)
  ≥ 3000 27.4 1.44 (0.91–2.23) 1.48 (0.94–2.32) 27.2 1.50 (0.88–2.56) 1.20 (0.66–1.71) 28.1 1.24 (0.48–3.21) 1.34 (0.37–4.95)
Education
  ≤ 6 years 17.5 1.0 1.0 14.6 1.0 1.0 24.6 1.0 1.0
 7–11 years 22.7 1.33 (0.86–2.06) 1.40 (0.88–2.22) 24.7 1.88 (1.11–3.19) 1.93 (1.11–3.35) 15.9 0.51 (0.22–1.20) 0.46 (0.17–1.24)
  ≥ 12 years 28.6 1.78 (1.10–2.87) 1.72 (1.00–2.96) 26.9 2.09 (1.18–3.72) 1.87 (1.00–3.51) 35.9 1.43 (0.56–3.64) 1.34 (0.40–4.48)
  1. OR odds ratio, CI confidence interval, SPC second primary cancer
  2. aSubjects who received gastroscopy or double-contrast upper gastrointestinal series within 2 years were defined as lung cancer survivors with appropriate stomach cancer screening
  3. bAdjusted for age, stage, marital status, education, family income status, smoking status, alcohol consumption, receiving recommendation for other cancer screening, and the perception of secondary cancer risks